HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leckman, J. F. Articles by Cohen, D. J. Search for Related Content PubMed PubMed Citation Articles by Leckman, J. F. Articles by Cohen, D. J.

Short- and long-term treatment of Tourette's syndrome with clonidine

A clinical perspective

Child Study Center, the Children's Clinical Research Center, and the Departments of Pediatrics, Psychiatry, and Neurology, Yale University School of Medicine, New Haven, CT.

Thirteen patients with Gilles de la Tourette's syndrome were treated with clonidine (0.125 to 0.3 mg/d) for at least 60 weeks. In a single-blind, placebo-controlled trial, 6 of the 13 patients were judged to be unequivocal responders to clonidine, and 6 other patients had an equivocal response. There was significant improvement in motor and phonicties, as well as in associated behavior problems, and there were no serious side effects. Tolerance to clonidine did not develop. Further placebo-controlled, randomized, double-blind studies of clonidine in Tourette's syndrome are needed to establish the drug's efficacy.

Address correspondence and reprint requests to Dr. Leckman, Child Study Center, Yale University School of Medicine, PO Box 3333, New Haven, CT 06510.

Supported in part by NIMH Grant MH30929, NIH Grant RR00125. NICHD Grant HD03008, the Solomon R. & Rebecca D. Baker Foundation, Inc., Mr. Leonard Berger, the William T. Grant Foundation (Dr. Leckman), the Gateposts Foundation (Dr. Cohen), and the John Merck Fund (Dr. Leckman).

Accepted for publication June 22, 1984.

This article has been cited by other articles:

				V. L. Vetter, J. Elia, C. Erickson, S. Berger, N. Blum, K. Uzark, and C. L. Webb Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing Circulation, May 6, 2008; 117(18): 2407 - 2423. [Full Text] [PDF]

				T. S. Edgar Oral Pharmacotherapy of Childhood Movement Disorders J Child Neurol, January 1, 2003; 18(1_suppl): S40 - S49. [Abstract] [PDF]

				M. M. Robertson Tourette syndrome, associated conditions and the complexities of treatment Brain, March 1, 2000; 123(3): 425 - 462. [Abstract] [Full Text] [PDF]

				M. M. Robertson, D. A. Scull, V. Eapen, and M. R. Trimble Risperidone in the treatment of Tourette syndrome: a retrospective case note study J Psychopharmacol, January 1, 1996; 10(4): 317 - 320. [Abstract] [PDF]

				J. F. Leckman, M. T. Hardin, M. A. Riddle, J. Stevenson, S. I. Ort, and D. J. Cohen Clonidine Treatment of Gilles de la Tourette's Syndrome Arch Gen Psychiatry, April 1, 1991; 48(4): 324 - 328. [Abstract] [PDF]

				T. W. Uhde, M. B. Stein, B. J. Vittone, L. J. Siever, J.-P. Boulenger, E. Klein, and T. A. Mellman Behavioral and Physiologic Effects of Short-term and Long-term Administration of Clonidine in Panic Disorder Arch Gen Psychiatry, February 1, 1989; 46(2): 170 - 177. [Abstract] [PDF]

				J. F. Leckman, S. Ort, K. A. Caruso, G. M. Anderson, M. A. Riddle, and D. J. Cohen Rebound Phenomena in Tourette's Syndrome After Abrupt Withdrawal of Clonidine: Behavioral, Cardiovascular, and Neurochemical Effects Arch Gen Psychiatry, December 1, 1986; 43(12): 1168 - 1176. [Abstract] [PDF]